MAP2K7 and endometrial cancer: Based on what has been discovered regarding the molecular and genetic makeup of endometrial cancers, targeted therapies beyond mTOR and CDK4/6 have the possibility to increase activity when combined with hormonal therapy (e.g., MEK inhibitors and tyrosine kinase inhibitors [57]).